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To the Editor: Cornelius et 
al. (1) addressed the potential of 
Campylobacter ureolyticus as an 
emerging pathogen by conducting 
a molecular study on 128 diarrheal 
specimens and 49 fecal samples 
from healthy volunteers. Reporting 
the identifi cation of C. ureolyticus in 
12 (24.5%) of 49 healthy volunteers, 
a number that they compared with 
our fi nding of 349 (23.8%) from 
Campylobacter spp.–positive samples 
(2), the authors concluded that C. 
ureolyticus species “are unlikely 
causes of diarrhea,” an assertion with 
which we take issue.
This interpretation does not 
take into account that our screening 
involved 7,194 symptomatic patients: 
a sample size 40× greater than that of 
Cornelius et al. In this context, the 
likely carriage rate for C. ureolyticus 
is 1.15%. Also, our assay, which has 
a limit of detection in the picomolar 
range, is likely comparable with, if 
not greater than, that of Cornelius et 
al. (1).
Accounting for variations in 
geographic location and detection 
methods, a detection rate of 24.5% in 
healthy volunteers (overall detection 
rate 14.7%) is high in contrast to our 
reported rate of 1.15%. One possible 
explanation for this discrepancy 
is that Cornelius et al. “did not 
specifi cally exclude volunteers who 
had had gastrointestinal disturbances 
in the 10 days before sampling,” 
Campylobacter can be shed in 
feces for <4 weeks after infection. 
Also, Cornelius et al. (1) noted the 
possibility of “genetically distinct 
but phenotypically indistinguishable 
genomospecies differing in their 
pathogenic potential” to account 
for the presence of the emerging 
pathogen C. concisus in healthy 
volunteers and patients with diarrheal 
illness. This may also apply for C. 
ureolyticus.
We reported a strong seasonal 
prevalence of C. ureolytcius and a 
bimodal age distribution (2). The 
lack of any related details from 
Cornelius et al. may undermine their 
reported detection rates. These factors 
strongly suggest that the statement, 
“these species are unlikely causes of 
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In Response: In response to the 
letter by Bullman et al. (1), a major as-
pect of our study (2) was to compare 
epsilonproteobacterial populations in 
healthy persons and those who have 
diarrhea. We have not examined as 
many diarrheal samples as Bullman et 
al. (3). However, in contrast with their 
study, we have examined samples 
from persons with no evident disease 
manifestations. Because the presence 
of an agent during disease is not proof 
of causation, we believed that a base-
line for comparison was needed. Cam-
pylobacter ureolyticus was found in 
a greater proportion of samples from 
healthy persons (24%) than samples 
from persons who had diarrhea (11%) 
(p = 0.041, by χ2 test). 
Samples from healthy persons 
were tested on 2 occasions: 18 sam-
ples in September 2007 (New Zea-
land spring) at the Institute of En-
vironmental Science and Research, 
Christchurch, in the  workplace, and 
31 samples in June 2009 (New Zea-
land winter), at Christchurch Hospi-
tal under the guidance of a clinician. 
We have no reason to believe any of 
the workplace samples were provided 
when volunteers had diarrhea, par-
ticularly considering our workplace 
guidelines and staff characteristics. 
In each testing round, 6 fecal samples 
had positive test results for C. ureo-
lyticus. These periods equate to the 
peak and trough periods described by 
Bullman et al. (3). We were unable to 
provide many details regarding sam-
pling in our paper because of space 
constraints.
Considering our baseline com-
parisons of healthy persons with those 
who had diarrhea, we affi rm our con-
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clusions are reasonable and that C. 
ureolyticus is an unlikely cause of 
acute diarrheal disease. Similarly, C. 
ureolyticus (previously classifi ed as 
Bacteroides ureolyticus) has been de-
tected in patients with Crohn’s disease 
and in controls (4). However, different 
subtypes or undescribed subspecies 
may be pathogenic: some strains ex-
hibit certain pathogenic characteristics 
in vitro (5) and others yield amplifi ed 
fragment length polymorphism pro-
fi les that are visually quite distinct 
from others (6). Host factors also can-
not be discounted.
Stephen L.W. On 
and Angela J. Cornelius
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